I'm back with the third list of clinical trials covering experimental drugs currently undergoing testing in phase II and phase III studies by drug and biotech companies.

This installment, like the previous two, covers clinical trials with results expected in 2009. You can find part one here and part two here.

These lists also serve as companions to the column I posted on June 3.

Unlike U.S. Food and Drug Administration drug approvals, which are more precisely timed, the release dates for data from clinical trials is a bit fuzzier, so the timelines here are culled from company guidance when possible.

I put this calendar together using company reports, sell-side research and the BioMedTracker service from Sagient Research, a subscription-based tool for keeping track of biotech and drug catalysts.

Before I get to the part three of the clinical trials calendar, I want to review a few of the clinical trials from the previous installments that have reported results already.

On June 24, Jazz Pharmaceuticals ( JAZZ) announced positive results from the second of two phase III studies of JZP-6 in fibromyalgia. Jazz shares, trading at $4.30 at the time of the announcement, rose to an intraday high of $5.27 the following day. The stock was recently trading at $3.79.

Celgene ( CELG) posted positive results from a phase II study of apremilast in patients with psoriatic arthritis on June 15. As a large-cap biotech, Celgene's stock price is probably not as sensitive to phase II data, although shares have jumped from $42 to $48.33 since the apremilast data were released.

On a less positive note, Insmed ( INSM) shares dropped from $2.33 to $1.08 after the company released negative results from a phase II study of its drug iPlex in muscular dystrophy. The stock was most recently trading at $1.09.

Now, the new clinical trials list:

Company: Myriad Pharmaceuticals ( MYRXV)
Drug/indication: Azixa for cancer
Clinical trial event: Phase II results in brain cancer and metastatic melanoma
Timing: 2009

Myriad Pharmaceuticals is a new company focused on drug discovery and development that was spun out of genetics diagnostics maker Myriad Genetics ( MYGN). The first test of strength for Myriad Pharmaceuticals' pipeline will come from the results of the phase II Azixa studies.

Company: Onyx Pharmaceuticals ( ONXX)
Drug/indication: Nexavar for breast cancer
Clinical trial event: Phase II study results
Timing: 2009

Onyx believes Nexavar has more utility in cancer than just its current approvals for liver and kidney cancers. Two phase II studies in breast cancer patients that combine Nexavar with the chemotherapy drugs gemcitabine and paclitaxel, respectively, will help determine whether Nexavar's market potential can be expanded.

Company: Optimer Pharmaceuticals ( OPTR)
Drug/indication: Fidaxomicin (OPT-80) for clostridium difficile infection
Clinical trial event: Phase III results
Timing: Fourth quarter 2009

In the first phase III study last year, fidaxomicin outperformed vancomycin, the current standard of care for patients infected with the clostridium difficile bacteria. Optimer is hoping that the second phase III study yields the same positive results, which will allow the company to seek the drug's marketing approval.

Company: Osiris Therapeutics ( OSIR)
Drug/indication: Prochymal for graft-vs.-host disease
Clinical trial event: Phase III results
Timing: Fourth quarter

I must acknowledge a negative bias with respect to Osiris because the stock was a short recommendation in my model portfolio. The reason is simple: I don't believe in the efficacy of Prochymal, a concoction derived from mesenchymal stem cells. Failed Prochymal studies in lung disease and Crohn's disease lend credence to my skepticism, I believe, but the ultimate judgment on Prochymal will come when data from two phase III studies in graft-vs.-host disease are released.

Company: Oxigene ( OXGN)
Drug/indication: Zybrestat for non-small cell lung cancer
Clinical trial event: Phase II results
Timing: 2009

The phase II study adds Zybrestat to a standard first-line regimen for lung cancer for Avastin and chemotherapy. The study enrolled 60 patients and is using progression-free survival as the primary endpoint.

Company: Protalix Biotherapeutics ( PLX)
Drug/indication: prGCD for Gaucher's disease
Clinical trial event: Phase III results
Timing: Fourth quarter

Protalix says it will seek FDA approval for prGCD if results are positive from this pivotal phase III study. The drug, if approved, would compete against Genzyme's Cerezyme.

Company: Repros Therapeutics ( RPRX)
Drug/indication: Proellex for uterine fibroids
Clinical trial event: Phase III results
Timing: Fourth quarter

This is the first of two phase III studies required for Repros to seek regulatory approval of Proellex. Results from the second study are expected early next year.

Company: Vertex Pharmaceuticals ( VRTX)
Drug/indication: Telaprevir for hepatitis C
Clinical trial event: Phase II twice-daily dosing data
Timing: 2009

Vertex will release final data from a phase II study investigating whether telaprevir can be dosed twice daily instead of three times daily.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Goodbye

Goodbye

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio